To the Editors,

We read with great interest the article by Occhipinti and Pastorelli.^[@CIT0001]^ The authors report their experiences and challenges in managing patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. We complement this important information by presenting a survey conducted among German patients with IBD regarding their personal evaluation of their work-related risk of contracting SARS-CoV-2. In Europe---as in many other regions of the world---people are now facing contact restrictions because of the COVID-19-pandemic. Thus, returning to work becomes an increasingly important issue---also from a socioeconomic point of view. Considering the viewpoint of patients with IBD is very important for the patients' health care management in the next phase of the pandemic.

An online questionnaire was completed by 405 patients, who were recruited via social media channels of IBD self help groups (for details see [Table 1](#T1){ref-type="table"}). Of the participants, 60.2% feared a SARS-CoV-2 infection and 57.6% were worried about going to work because of a potentially increased infection risk. Half of the participants (49.4%) believed that IBD predisposed them to a higher risk of contracting SARS-CoV-2 compared with their colleagues who did not have IBD. Consequently, 18.8% of the survey participants received a "preventive" sick certificate for a duration of more than 7 days from their general practitioner even if they did not show any symptoms of an infection. Of the participants being treated using azathioprine/6-mercaptopurine, 27.1% reported using this strategy, as did 26.5% of those treated using anti-tumor necrosis factor α treatment, 25% of those treated using prednisolone, 20.7% of those treated using ustekinumab, 19.1% of those treated using budesonide, and 10.8% of those treated using vedolizumab.

###### 

Demographic and Disease-Related Characteristics of the Survey Participants

  Demographic Characteristics                           Number   Percentage
  ----------------------------------------------------- -------- ------------
  Women                                                 320      79.0
  Age, y (mean age ± SD)                                40.9     13.3
  Smoker                                                66       16.3
  Disease                                                        
   Crohn disease                                        232      58.1
   Ulcerative colitis                                   161      40.4
   IBD unclassified                                     5        1.3
   Microscopic colitis                                  1        0.3
  Medical caretaker (IBD)                                        
   University outpatient clinic                         52       13.3
   Specialized medical care center                      90       23.0
   Gastroenterologist                                   205      52.4
   Internal specialist                                  29       7.4
   General practitioner                                 13       3.3
   Nonmedical practitioner                              0        0.0
   None                                                 2        0.5
  Number of visits in last 12 months to IBD caretaker   7.6      7.53
  Medication (multiple answers allowed)                          
   Mesalazine                                           119      20.6
   Sulfasalazine                                        11       1.9
   Azathioprine/6-mercaptopurine                        70       12.1
   Budesonide                                           57       9.9
   Prednisolone                                         51       8.8
   Anti-tumor necrosis factor α antibodies              136      23.5
   Vedolizumab                                          41       7.1
   Ustekinumab                                          36       6.2
   Tofacitinib                                          9        1.6
   Antibiotics                                          6        1.0
   Methotrexate                                         10       1.7
   Cyclosporine                                         0        0.0
   Tacrolimus                                           2        0.3
   None                                                 30       5.2
  Disease activity (patients' report)                            
   Remission                                            126      31.8
   Mild                                                 160      40.4
   Moderate                                             84       21.2
   Severe                                               26       6.6

Liberally issuing preventive sick certificates may be an exceptional strategy used for individual patients experiencing stressful life circumstances. However, during the COVID-19 pandemic, the survey participants have used this coping strategy frequently. They also reported that they have delayed the decision on whether it is safe to go to work because of divergent or ambiguous opinions of their physicians as well as expert opinions from other sources (internet sources, media).

Clearly, the ability to work is very important to most patients with IBD. Still, returning to work is often hampered by uncertainties because of the pandemic. Therefore, straightforward recommendations stating clearly who is at risk and who should avoid which type of work are very important for managing the daily life of our patients. In addition, public financial support for patients who cannot go to work must be considered. When counseling patients, transparent and open communication regarding the available evidence is of crucial importance. Databases such as Secure-IBD^[@CIT0002]^ may be a helpful tool.
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